Cargando…

Adverse drug reactions with naltrexone: Experience from an addiction treatment center

Detalles Bibliográficos
Autores principales:	Sarkar, Siddharth, Addagadda, Sahithi Sri, Bhatia, Gayatri, Chadda, Rakesh Kumar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2021
Materias:	Letters to Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8214125/ https://www.ncbi.nlm.nih.gov/pubmed/34194072 http://dx.doi.org/10.4103/psychiatry.IndianJPsychiatry_94_20

Ejemplares similares

Disulfiram safety in alcohol use disorders: Experience from an addiction treatment center in India
por: Bhatia, Gayatri, et al.
Publicado: (2022)

Tramadol-Related Adverse Drug Reactions at an Addiction Psychiatry Setting: A Cross-Sectional Analysis
por: Dhagudu, Naveen Kumar, et al.
Publicado: (2019)

A Prospective Three-Months Naturalistic Follow-Up Study of Outcomes of Patients with Opioid Dependence Discharged on Buprenorphine or Oral Naltrexone
por: Singh, Virendra Vikram, et al.
Publicado: (2022)

Adverse cutaneous drug reactions
por: Adibi, Neda
Publicado: (2014)

Effects of naltrexone are influenced by childhood adversity during negative emotional processing in addiction recovery
por: Savulich, G, et al.
Publicado: (2017)

Adverse drug reaction and causality assessment scales
por: Zaki, Syed Ahmed
Publicado: (2011)

Clinical causality assessment for adverse drug reactions
por: Parida, Satyen
Publicado: (2013)

Naltrexone-induced psychosis in a patient with alcohol use disorder
por: Ruei-Yuan, Hu, et al.
Publicado: (2023)

Adverse drug reaction monitoring in psychiatry out-patient
por: Tandon, Vishal
Publicado: (2012)

Adverse drug reactions in the era of multi-morbidity and polypharmacy
por: Birriel, T. Javier, et al.
Publicado: (2015)

Adverse drug reactions due to ophthalmic drugs: Reporting system in India
por: Kalaiselvan, Vivekanandan, et al.
Publicado: (2016)

Reasons of Disciplinary Discharges from a Tertiary Care De-addiction Setting in India
por: Sarkar, Siddharth, et al.
Publicado: (2017)

The frequency of agitation due to inappropriate use of naltrexone in addicts
por: Siadat, Sima, et al.
Publicado: (2014)

Rheumatic Immuno-related Adverse Events following Immunotherapy with Checkpoint Inhibitors: Adverse Drug Reaction, or Other?
por: Manzo, Ciro
Publicado: (2021)

Drug consumption during prolonged lockdown due to Covid-19 as observed in French addiction center
por: Chappuy, Mathieu, et al.
Publicado: (2021)

Incident Reporting of Adverse Drug Reaction to Intravenous Ranitidine in an Emergency Department
por: Sud, Saurabh, et al.
Publicado: (2018)

Serious adverse drug reactions with hydroxychloroquine: a pharmacovigilance study in Vigibase®
por: Montastruc, Jean-Louis, et al.
Publicado: (2020)

Views about responsibility for alcohol addiction and negative evaluations of naltrexone
por: Johnson, Rebecca A, et al.
Publicado: (2015)

Comment on “Effectiveness of Naltrexone in the Prevention of Delayed Respiratory Arrest in Opioid-Naive Methadone-Intoxicated Patients”
por: Kessler, Benjamin D., et al.
Publicado: (2014)

Comment on “Effectiveness of Naltrexone in the Prevention of Delayed Respiratory Arrest in Opioid-Naive Methadone-Intoxicated Patients”
por: Aghabiklooei, Abbas, et al.
Publicado: (2015)

Comment on “Review of Case Narratives from Fatal Overdoses Associated with Injectable Naltrexone for Opioid Dependence”
por: Silverman, Bernard, et al.
Publicado: (2018)

Life threatening opioid withdrawal syndrome due to inadvertent naltrexone administration and lifesaving result by clonidine
por: Kurmi, Jayanta, et al.
Publicado: (2020)

System of adverse drug reactions reporting: What, where, how, and whom to report?
por: Kalaiselvan, Vivekanandan, et al.
Publicado: (2015)

Adverse reactions to nonsteroidal anti-inflammatory drugs and hypersensitivity to lipid transfer proteins
por: Nucera, Eleonora, et al.
Publicado: (2016)

Adverse drug reactions reporting in Turkey and barriers: an urgent need for pharmacovigilance education
por: Khan, Zakir, et al.
Publicado: (2020)

Adverse drug reactions of itolizumab in COVID-19 patient: A case report
por: Mohammed, Ziauddin, et al.
Publicado: (2022)

A cross-sectional study of adverse drug reactions reporting among doctors of a private medical college in Bihar, India
por: Panja, Buddhadev, et al.
Publicado: (2015)

Prognostic significance of psychopathology in the abstinence from opiate addiction
por: Lal, Rakesh
Publicado: (1990)

Mental Healthcare Act, 2017, and addiction treatment
por: Nadkarni, Abhijit, et al.
Publicado: (2020)

Club Drugs in India: An Analysis of Newspaper Reports
por: Kathiresan, Preethy, et al.
Publicado: (2021)

Discouraging adverse drug reactions reporting culture: Just a tip of the ‘Gullible Prescribing’
por: Mohammed, Imran
Publicado: (2013)

Proposal for Publishing and Parallel Reporting of Case Reports on Adverse Drug Reactions to Authorities by Physicians
por: Sickmüller, Barbara, et al.
Publicado: (2013)

Adverse reactions of drugs specifically used for treatment of SARS-CoV-2 infection
por: Tang, Mi, et al.
Publicado: (2021)

Adverse reactions of drugs specifically used for treatment of SARS-CoV-2 infection
por: Tang, Mi, et al.
Publicado: (2021)

Differences in reporting of adverse drug reactions due to COVID-19 vaccines depending on the reporter
por: Pardo-Cabello, Alfredo Jose, et al.
Publicado: (2023)

Naltrexone‐induced drug eruption
por: Heck, Johannes, et al.
Publicado: (2020)

Letter to the editor—a need to strengthen the adverse drug reaction reporting during COVID-19
por: Bakshi, Satvinder Singh, et al.
Publicado: (2021)

A rare association of schizophrenia and Mayer-Rokitansky-Küster-Hauser syndrome
por: Bhad, Roshan, et al.
Publicado: (2015)

Pharmacovigilance in drugs used in the treatment of drug dependence
por: Thota, Anusha, et al.
Publicado: (2017)

Comment on: An Insight Into Z-Drug Abuse and Dependence: An Examination of Reports to the European Medicines Agency Database of Suspected Adverse Drug Reactions
por: Jouanjus, Emilie, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_q60uqr56j40rpveuv3odguoeji